Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PHARMERICA (DOSE) - Undervalued Growth Company -- Ignore unavailable to you. Want to Upgrade?

To: Joe Dancy who wrote (12)	11/9/1998 10:35:00 AM
From: jimiboy	Read Replies (1) \| Respond to of 24

My personal overreaction to today's earnings(we only lost a buck forty two a share!) and other items is that they push DOSE 6 mos. away (at best) from a real breakout. I think you had it perfect. They have simply over done it on acquisitions. I've been there. Each new acquisition will be slightly different and after awhile nothing is going well. The retention of DLJ to study to study strategic alternatives just puts the stock in Limbo. My bet DLJ is going to recommend shedding of some of the acquisitions. It could be a long process. Whenever I'm this negative I've been wrong. I hope the trend continues.